For pancreatic carcinoma, it has been reported that the Rb tumour-suppressive pathway is abrogated in near to all studied cases and that this disruption is caused exclusively by inactivation of the p16INK4a gene. The gene discussed is CDKN2A; the disease is exocrine pancreatic carcinoma.